Form 15-12G - Securities registration termination [Section 12(g)]
May 14 2024 - 4:29PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-39458
MEDICENNA THERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)
2 Bloor St. W., 7th Floor
Toronto, Ontario M4W 3E2, Canada
(416) 648-5555
(Address, including zip code, and telephone number, including area code,
of registrant’s principal executive offices)
Common Shares, without par value
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports
under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon
to terminate or suspend the duty to file reports:
|
|
|
Rule 12g-4(a)(1) |
|
☒ |
Rule 12g-4(a)(2) |
|
☐ |
Rule 12h-3(b)(1)(i) |
|
☒ |
Rule 12h-3(b)(1)(ii) |
|
☐ |
Rule 15d-6 |
|
☐ |
Rule 15d-22(b) |
|
☐ |
Approximate number of holders of record as of the certification or notice date: 104
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, Medicenna
Therapeutics Corp. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
|
|
|
|
|
|
|
|
|
|
|
Medicenna Therapeutics Corp. |
|
|
|
|
Date: May 14, 2024 |
|
|
|
By: |
|
/s/ Fahar Merchant
|
|
|
|
|
Name: |
|
Fahar Merchant |
|
|
|
|
Title: |
|
President and Chief Executive Officer |
Medicenna Therapeutics (NASDAQ:MDNA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Medicenna Therapeutics (NASDAQ:MDNA)
Historical Stock Chart
From Aug 2023 to Aug 2024